{'fraction_non_alphanumeric': 0.02564102564102564, 'fraction_numerical': 0.0, 'mean_word_length': 5.452173913043478, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Activity of ceftazidime and newer antibiotics against Gram-negative bacilli.

Ceftazidime is a new parenterally applicable cephalosporin with high beta-lactamase stability and a remarkable activity against the Enterobacteriaceae and non-fermentative Gram-negative bacilli. The in-vitro activity of ceftazidime in general is comparable with that of cefotaxime and moxalactam. Ceftazidime proved the most active of the newer cephalosporins against Ps. aeruginosa, Ps. cepacia, Ser. marcescens and Pr. vulgaris. The bactericidal effectiveness of ceftazidime is excellent against the majority of species tested. Ceftazidime is a promising new beta-lactam antibiotic and the first clinical results seem to confirm the excellent in-vitro activity.